Literature DB >> 11840458

Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo.

Azzudin E Gharavi1, Silvia S Pierangeli, Ricardo G Espinola, Xiaowei Liu, Margaret Colden-Stanfield, E Nigel Harris.   

Abstract

OBJECTIVE: To characterize the binding and functional properties of antiphospholipid antibodies (aPL) induced by immunization with a viral peptide and to determine whether aPL are pathogenic in vivo.
METHODS: Ten murine monoclonal aPL were generated from spleen cells of PL/J mice immunized with TIFI, a phospholipid-binding peptide spanning Thr(101)-Thr(120) of ULB0-HCMVA from human cytomegalovirus (CMV), which shares structural similarity with the phospholipid-binding site of beta(2)-glycoprotein I (beta(2)GPI).
RESULTS: The antibodies generated had aPL activity that was inhibited by cardiolipin liposomes, and this inhibition was enhanced in the presence of beta(2)GPI. Some of the antibodies exhibited binding to cultured endothelial cells in vitro, and some had lupus anticoagulant activity. Injection with 2 of the monoclonal aPL in mice resulted in a significant increase in the number of leukocytes adhering to endothelial cells and enhanced thrombus formation in vivo.
CONCLUSION: These results indicate that aPL induced by immunization with a phospholipid-binding CMV peptide are pathogenic in vivo. The results also suggest a mechanism (molecular mimicry) by which pathogenic aPL may be generated in patients with antiphospholipid syndrome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11840458     DOI: 10.1002/art.10130

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  43 in total

Review 1.  Human cytomegalovirus infection and atherothrombosis.

Authors:  Milan Popović; Katarina Smiljanić; Branislava Dobutović; Tatiana Syrovets; Thomas Simmet; Esma R Isenović
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

Review 2.  Antiphospholipid antibodies and infections.

Authors:  R A Asherson; R Cervera
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

Review 3.  Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients.

Authors:  R Cervera; R A Asherson; M L Acevedo; J A Gómez-Puerta; G Espinosa; G De La Red; V Gil; M Ramos-Casals; M García-Carrasco; M Ingelmo; J Font
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

Review 4.  Antiphospholipid antibodies in young adults with stroke.

Authors:  Robin L Brey
Journal:  J Thromb Thrombolysis       Date:  2005-10       Impact factor: 2.300

Review 5.  Infectious origin of the antiphospholipid syndrome.

Authors:  Y Shoenfeld; M Blank; R Cervera; J Font; E Raschi; P-L Meroni
Journal:  Ann Rheum Dis       Date:  2006-01       Impact factor: 19.103

Review 6.  From molecular mimicry to cross-reactivity or pathogen expansion? A hypothesis.

Authors:  Alexander P Rozin
Journal:  Clin Rheumatol       Date:  2006-06-29       Impact factor: 2.980

Review 7.  Intravenous immunoglobulin therapy in antiphospholipid syndrome.

Authors:  Emiliana Konova
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

8.  Human cytomegalovirus pp65 lower matrix protein: a humoral immunogen for systemic lupus erythematosus patients and autoantibody accelerator for NZB/W F1 mice.

Authors:  M Chang; M-R Pan; D-Y Chen; J-L Lan
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

Review 9.  Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome.

Authors:  José Fidel Baizabal-Carvallo; Cecilia Bonnet; Joseph Jankovic
Journal:  J Neural Transm (Vienna)       Date:  2013-04-13       Impact factor: 3.575

10.  Acute phase phospholipids related to the cardiolipin of mitochondria in the sera of patients with chronic fatigue syndrome (CFS), chronic Ciguatera fish poisoning (CCFP), and other diseases attributed to chemicals, Gulf War, and marine toxins.

Authors:  Yoshitsugi Hokama; Cara Empey-Campora; Cynthia Hara; Nicole Higa; Nathaniel Siu; Rachael Lau; Tina Kuribayashi; Kenichi Yabusaki
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.